Inflammatory Bowel Disease: Current Status and Future Perspectives
In today’s crowded IBD clinical trial landscape, it can be difficult to complete your study as quickly and efficiently as possible. Being aware of the unique challenges that come with IBD trials can help you prepare and pivot more effectively when complications arise. In this white paper, Dr. Maxim Kosov, Senior Medical Advisor at PSI, breaks down recent trends in IBD clinical research, including insights into patient recruitment and retention.
Inflammatory Bowel Disease: Current Status and Future Perspectives offers insights into recent trial and research developments that will most impact study design and operationalization for various IBD therapies and indications. Download our new white paper to learn about:
- IBD epidemiology, patient risk factors, and cost drivers
- Current diagnostic and treatment methods
- Common clinical trial challenges and methods for patient enrollment and retention
View a sneak peek below
Inflammatory bowel disease (IBD) is an umbrella term that covers several clinical conditions, with two of them being the most common: Ulcerative Colitis (UC), which is limited to the colonic mucosa; and Crohn’s Disease (CD), which potentially affects any segment of the gastrointestinal tract from the mouth to the anus.
Both UC and CD are chronic, lifelong inflammatory diseases with a pattern of flare-ups and remission. While we have learned a lot about the predisposing factors, clinical symptoms, pathways, pathology, and genetics, the exact cause of these diseases remains unknown. The number of clinical trials aimed at the discovery of novel therapeutic options is increasing annually. But with more trials comes increasing complexity and challenges.
As a result, while we have come a long way in developing options to treat the symptoms of the diseases, we do not yet have a definitive treatment or cure. These diseases remain highly debilitating and, while no longer fatal in industrialized countries with the current state of medicine, continue to have a negative impact on the overall quality of life for the patient. This white paper will discuss UC and CD’s respective epidemiology and risk factors, current diagnostic and treatment approaches, and considerations for designing effective clinical trials.
Discover the Latest IBD Insights in our Latest Whitepaper
ABOUT THE AUTHOR
Maxim Kosov, MD, PH.D.
PSI SENIOR MEDICAL ADVISOR
Maxim Kosov, MD, Ph.D., is a Senior Medical Advisor at PSI CRO AG (USA). He graduated from Pediatric Medical Academy in Saint-Petersburg, Russia, in 1993 and worked as an intensive care physician in neonatal intensive care units of several major hospitals. He completed an international fellowship in neonatology at Albany Medical College, NY, USA, in 1996. In parallel with clinical work, Maxim was an Assistant Professor of the Faculty of Anesthesiology and Intensive Care at Saint-Peterburg Pediatric Medical Academy.
He joined PSI in 2004 and acted as a Medical Monitor in more than 60 clinical trials in various indications. He is the author/co-author of more than 50 publications and presented his research works at numerous international meetings and congresses, including annual European Respiratory Society (ERS) meetings in Berlin (2002), Stockholm (2002), and Drug Information Association (DIA) Congress in Hamburg (2016). He is a member of ASCO.
ABOUT PSI CRO
PSI CRO is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI’s global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors.
Global headquarters are based Switzerland at 113a Baarerstrasse, Zug 6300. www.psi-cro.com